BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//IAS-USA//NONSGML PDA Calendar Version 1.0//EN
CALSCALE:GREGORIAN
BEGIN:VEVENT
UID:b829f2b7a3baa64319960ad0b151cca5
ORGANIZER:registration@iasusa.org
DTSTAMP:20261025T182812Z
LOCATION:
SUMMARY:2018 IAS-USA Guidelines Update: Antiretroviral Treatment and Prevention of HIV Infection
DESCRIPTION:Overview\n\nAssessment of Needs\nThis webinar will review updated information on antiretroviral drugs for the treatment and prevention of HIV infection in adults. The IAS–USA offers this state-of-the-art activity as part of a nationwide continuing medical education (CME) effort for physicians on the evolving challenges of managing HIV infection.\nLearning Objectives\nOn completion of this webinar\, learners will be able to:\n\n 	Summarize the new IAS–USA guidelines on antiretroviral therapy for the treatment and prevention of HIV infection\n 	Apply the new IAS-USA guidelines to prevention\, initial therapy\, monitoring\, and managing treatment failure in HIV infection\n\nRegistration\nWho Should Attend\nThis webinar is designed for physicians who are actively treating or will be treating patients with HIV infection.\n\nThis activity is also relevant for registered nurses\, PharmDs\, and other health professionals.\n\nIndividual registration is required\, even if you are viewing as a group\, in order to receive CME credit or a certificate of participation.\n\nRegistration closes on Monday\, August 6\, 2018\, 4:00 PM (PT).\n\nCertificates will be available after the completion of the evaluation and claim form.\n\nFor more information or questions\, please contact the registration department at registration@iasusa.org or 415-544-9400.\nConflicts of Interest\nIn the interest of maintaining the independence of its CME activities\, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME)\, the IAS–USA requires all persons with control of content (eg\, faculty\, IAS–USA Board members\, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.\n\nThe ACCME defines a commercial interest as “any entity producing\, marketing\, re-selling\, or distributing health care goods or services consumed by\, or used on\, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned\, or controlled by\, an ACCME-defined commercial interest.”\n\nDr Saag has received research grants and support awarded to his institution from Gilead Sciences\, Inc\, Merck\, and ViiV Healthcare. He has also served as a consultant for Gilead Sciences\, Inc\, Merck\, and ViiV Healthcare. (Updated 08/06/18)\n\n\n\n\nContinuing Education Credits\n\nCME Credits\nThe International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.\n\nThe IAS–USA designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.\nNursing Credits\nEducational Review Systems is an approved approver of continuing nursing education by the Alabama State Nursing Association\, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. Provider # 5-115. This program is approved for 1.25 hours of continuing nursing education.\n\nEducational Review Systems is also approved for nursing continuing education by the state of California\, the state of Florida and the District of Columbia.\n\nThis program is approved for 1.25 hours of pharmacotherapy credit.\nPharmacy Credits\n Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 1.25 hours (0.125 CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.\nUAN # 0761-9999-18-228-L02-P\n\n\n\n\nGrant Support\n\n\nThis activity is part of the IAS–USA national educational effort that is funded\, in part\, by charitable contributions from commercial companies. Per IAS–USA policy\, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity\, including its content\, development\, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.\n\nPLATINUM SUPPORTERS\nGilead Sciences\, Inc\nViiV Healthcare\n\nSILVER SUPPORTERS\nJanssen Therapeutics\nMerck\nFrequently Asked Questions\nView our list of FAQs about attending a webinar.\n\nFurther Questions?\nPlease contact the registration department at registration@iasusa.org or 415-544-9400.
STATUS:CONFIRMED
CATEGORIES:Webinars
URL;VALUE=URI:https://www.iasusa.org/events/webinar-2018-saag/
DTSTART:20180807T170000Z
DTEND:20180807T181500Z
END:VEVENT
END:VCALENDAR